Group 1 - Gilead Sciences, Inc. (NASDAQ:GILD) is recognized as one of the best drug stocks to buy currently, with a Buy rating maintained by Simon Baker CFA from Redburn Atlantic and a price target set at $143.00 [1] - The company received marketing authorization for Yeytuo (lenacapavir) from the European Commission, marking it as the first and only twice-yearly injectable HIV-1 capsid inhibitor approved for pre-exposure prophylaxis (PrEP) in the EU member states [2] - Gilead Sciences operates in over 35 countries and focuses on developing medicines for serious diseases, including cancer, HIV, viral hepatitis, and COVID-19, with a portfolio that includes drugs like AmBisome, Atripla, and Biktarvy [2]